Skip to main content

Table 2 Summary of the sensitivity analysis

From: A refined and updated health impact assessment of the Global Programme to Eliminate Lymphatic Filariasis (2000–2020)

Parameter   Baseline hydrocele average estimate (range) Baseline lymphedema average estimate (range) Sources
Pre-control burden
 Percentage of the at-risk population that develop clinical disease   2.08% (1.04%) 1.25% (0.63%) [16]
Disability weights
 Disability weights related to chronic disease   0.128 (0.086–0.180) 0.109 (0.073–0.154) [17]
 Disability weight for ADL episodes   0.051 (0.032–0.074) 0.051 (0.032–0.074) [17]
Disease progression & incidence rates
 Percentage of clinical patients who experience ADL episodes per year   70% (45–90%) 95% (90–95%) [26,27,28,29,30,31,32,33,34]
 Frequency of ADL episodes for clinical patients (in absence of MDA)   2 (0–7) per year 4 (0–7) per year [26,27,28,29,30,31,32,33,34]
 Average duration of an ADL episode   4 (1–9) days 4 (1–9) days [26,27,28,29,30,31,32,33,34]
 Mean age of the benefit cohorts (years)   Cohort 1: 20 (30)
Cohort 2: 20 (30)
Cohort 3: 30 (40)
Cohort 1: 20 (30)
Cohort 2: 20 (30)
Cohort 3: 30 (40)
 
Impact of treatment
 The reduction in transmission experienced by the treated population (Benefit cohort 1)   Year 1: 50% (35%)
Year 2: 75% (53%)
Year 3: 88% (62%)
Year 4: 94% (66%)
Year 5 95% (67%)
Year 1: 50% (35%)
Year 2: 75% (53%)
Year 3: 88% (62%)
Year 4: 94% (66%)
Year 5 95% (67%)
[12]
 Reduction in the frequency of ADL episodes by MDA (Benefit cohort 3)   50% (15–88%) 50% (15–88%) [35,36,37]
 Percentage of chronic disease alleviated by MDA (Benefit cohort 3)   10% (0–20%) 15% (0–30%) [35, 38,39,40,41,42,43]
  1. Based on Chu et al. [10], though updated where appropriate
  2. ADL acute adenolymphangitis, DALY disability-adjusted life year, MDA mass drug administration